COMMONWEALTH EQUITY SERVICES, LLC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.

Quarter-by-quarter ownership
COMMONWEALTH EQUITY SERVICES, LLC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$1,817
-21.2%
40,023
-2.5%
0.00%
-20.0%
Q2 2023$2,305
+26.4%
41,061
+1.8%
0.01%
+25.0%
Q1 2023$1,824
-12.1%
40,341
-21.0%
0.00%
-20.0%
Q4 2022$2,076
-100.0%
51,084
-52.4%
0.01%
-72.2%
Q3 2022$7,013,000
+148.2%
107,328
+130.8%
0.02%
+157.1%
Q2 2022$2,825,000
+4.4%
46,498
+7.8%
0.01%
+16.7%
Q1 2022$2,706,000
+0.9%
43,114
+21.8%
0.01%0.0%
Q4 2021$2,681,000
-37.6%
35,383
-7.8%
0.01%
-45.5%
Q3 2021$4,297,000
-24.2%
38,393
+9.6%
0.01%
-21.4%
Q2 2021$5,668,000
+54.4%
35,015
+16.2%
0.01%
+40.0%
Q1 2021$3,672,000
-13.9%
30,140
+8.2%
0.01%
-23.1%
Q4 2020$4,266,000
+106.4%
27,865
+12.7%
0.01%
+85.7%
Q3 2020$2,067,000
+12.6%
24,718
-1.0%
0.01%0.0%
Q2 2020$1,835,000
-1.7%
24,975
-43.3%
0.01%
-22.2%
Q1 2020$1,867,000
+0.4%
44,039
+44.2%
0.01%
+28.6%
Q4 2019$1,859,000
+149.2%
30,532
+67.7%
0.01%
+133.3%
Q3 2019$746,000
-11.1%
18,201
+2.2%
0.00%
-25.0%
Q2 2019$839,000
+39.6%
17,815
+5.9%
0.00%
+33.3%
Q1 2019$601,000
+65.1%
16,829
+32.1%
0.00%
+50.0%
Q4 2018$364,000
-38.3%
12,741
-4.3%
0.00%
-33.3%
Q3 2018$590,000
-18.8%
13,318
+7.6%
0.00%
-25.0%
Q2 2018$727,000
+176.4%
12,373
+114.3%
0.00%
+300.0%
Q1 2018$263,0005,7730.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q1 2023
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$31,294,00031.24%
NEA Management Company, LLC 1,590,002$365,593,00010.56%
Ariose Capital Management Ltd 37,900$2,379,0009.30%
ARK Investment Management 9,404,071$590,294,0002.46%
NIA IMPACT ADVISORS, LLC 80,082$5,027,0002.44%
Nikko Asset Management Americas, Inc. 4,619,747$291,044,0002.14%
PLUSTICK MANAGEMENT LLC 50,000$3,139,0001.98%
Integral Health Asset Management, LLC 120,000$7,532,0001.96%
Valiant Capital Management, L.P. 240,683$15,108,0001.73%
Deuterium Capital Management, LLC 18,000$1,130,0001.45%
View complete list of CRISPR THERAPEUTICS AG shareholders